Efficacy and Safety of ONCOXIN in Patients With Breast Fibrocystic Disease
Launched by CATALYSIS SL · Aug 27, 2009
Trial Information
Current as of June 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients with clinical and ultrasonographic confirmation of breast fibrocystic disease.
- • Patients older than 20 years.
- • Female patients.
- • Informed consent.
- Exclusion Criteria:
- • Presents of another disease not well controlled.
- • Pregnant women or lactating.
- • Patient which are receiving another products from other investigations trials.
About Catalysis Sl
Catalysis SL is a dynamic clinical research organization dedicated to advancing innovative therapies through comprehensive clinical trial management and support. With a focus on enhancing patient outcomes, Catalysis SL specializes in the design, execution, and oversight of clinical studies across various therapeutic areas. Our team of experienced professionals is committed to ensuring regulatory compliance, data integrity, and patient safety, while fostering collaboration with pharmaceutical and biotechnology companies. By leveraging cutting-edge technologies and methodologies, Catalysis SL strives to accelerate the development of new treatments, ultimately contributing to the improvement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Havana, , Cuba
Patients applied
Trial Officials
Daisy Hernández, MD
Principal Investigator
Ramón González Coro Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials